Literature DB >> 12714159

Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.

Wright B Lauten1, Qamar A Khan, Sanjay Rajagopalan, Stamatios Lerakis, Syed T Rahman, Sampath Parthasarathy, Bobby V Khan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714159     DOI: 10.1016/s0002-9149(03)00161-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  6 in total

1.  Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.

Authors:  L M Biasucci; M Lombardi; M Piro; G Di Giannuario; G Liuzzo; F Crea
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

Review 2.  Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Authors:  Katherine F Croom; Monique P Curran; Karen L Goa; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Cardiovascular effects of losartan and its relevant clinical application.

Authors:  Feichao Xu; Caiping Mao; Yali Hu; Can Rui; Zhice Xu; Lubo Zhang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

5.  Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.

Authors:  Sheldon Tobe; Kalina Kawecka-Jaszcz; Faiez Zannad; George Vetrovec; Rajiv Patni; Harry Shi
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

Review 6.  The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.

Authors:  Alessandra Del Fiorentino; Silvana Cianchetti; Alessandro Celi; Giulia Dell'Omo; Roberto Pedrinelli
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.